Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP; AVEX study investigators.

Lancet Oncol. 2013 Oct;14(11):1077-1085. doi: 10.1016/S1470-2045(13)70154-2. Epub 2013 Sep 10.

PMID:
24028813
2.

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.

Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González E, Grávalos C, Constenla M, Manzano JL, Losa F, Maurel J, Dueñas R, Massuti B, Gallego J, Aparicio J, Antón A, Aranda E.

Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29.

PMID:
23359181
3.

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12.

4.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E.

Oncologist. 2012;17(7):947-55. doi: 10.1634/theoncologist.2012-0048. Epub 2012 May 29.

5.

Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.

Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E, Carrato A, Marcuello E, Gómez A, Cabrera E, Queralt B, Gómez MJ, Guasch I, Etxeberría A, Alfaro J, Campos JM, Reina JJ, Aranda E.

Clin Colorectal Cancer. 2012 Sep;11(3):200-6. doi: 10.1016/j.clcc.2012.01.003. Epub 2012 Mar 14.

PMID:
22421001
6.

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

Sastre J, Grávalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, Manzano JL, Benavides M, Hidalgo M, Díaz-Rubio E, Aranda E.

Oncologist. 2012;17(3):339-45. doi: 10.1634/theoncologist.2011-0406. Epub 2012 Feb 23.

7.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors.

Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10.

8.

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M.

Br J Cancer. 2011 Jun 28;105(1):53-7. doi: 10.1038/bjc.2011.206. Epub 2011 Jun 7.

9.

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.

Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, Barnadas A, Marcuello E, Baiget M.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1319-27. doi: 10.1016/j.ijrobp.2011.01.025. Epub 2011 May 11.

PMID:
21570215
10.

Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: management and results at long-term follow-up.

Villavicencio H, Rodriguez Faba O, Palou J, Gausa L, Algaba F, Marcuello E.

Urol Int. 2010;85(3):281-6. doi: 10.1159/000316076. Epub 2010 Jul 30.

PMID:
20689253
11.

Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

Paré L, Paez D, Salazar J, Del Rio E, Tizzano E, Marcuello E, Baiget M.

Br J Clin Pharmacol. 2010 Aug;70(2):268-72. doi: 10.1111/j.1365-2125.2010.03683.x.

12.

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V.

Br J Cancer. 2010 Aug 10;103(4):581-9. doi: 10.1038/sj.bjc.6605776. Epub 2010 Jul 13.

13.

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.

Cancer Sci. 2010 Sep;101(9):2048-53. doi: 10.1111/j.1349-7006.2010.01621.x.

14.

Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.

Páez D, Paré L, Altés A, Sancho-Poch FJ, Petriz L, Garriga J, Monill JM, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1681-9. doi: 10.1007/s00432-010-0826-7. Epub 2010 Feb 18.

PMID:
20165956
15.

Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.

Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V.

J Clin Oncol. 2010 Feb 10;28(5):859-65. doi: 10.1200/JCO.2009.25.8541. Epub 2010 Jan 11.

PMID:
20065174
16.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, Cortés A, Barnadas A, Baiget M.

Br J Cancer. 2008 Oct 7;99(7):1050-5. doi: 10.1038/sj.bjc.6604671. Epub 2008 Sep 16. Erratum in: Br J Cancer. 2009 Apr 21;100(8):1368.

17.

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.

Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, Marcuello E, Constenla M, Cámara JC, Carrato A, Dueñas R, Reboredo M, Navarro M, Díaz-Rubio E.

Ann Oncol. 2009 Feb;20(2):251-7. doi: 10.1093/annonc/mdn557. Epub 2008 Aug 20.

18.

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.

Paré L, Salazar J, del Rio E, Baiget M, Altés A, Marcuello E, Paez D, Barnadas A.

J Clin Oncol. 2008 Jul 10;26(20):3468; author reply 3468-9. doi: 10.1200/JCO.2008.17.6479. No abstract available.

PMID:
18612168
19.

Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M.

Clin Cancer Res. 2008 Mar 15;14(6):1788-96. doi: 10.1158/1078-0432.CCR-07-1472.

20.

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.

Abad A, Massuti B, Antón A, Vega ME, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-Rubio E; Spanish Cooperative Group for Digestive Tumor Therapy.

Acta Oncol. 2008;47(2):286-92.

PMID:
17957505
21.

[Inversion of the sequence of surgery after neoadjuvant chemotherapy for synchronous liver metastases from colorectal cancer].

Marín-Hargreaves G, Artigas V, González JA, Martínez C, Marcuello E, Trías-Folch M.

Cir Esp. 2007 Oct;82(4):235-7. Spanish.

22.

Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?

Paré L, Marcuello E, Altés A, del Rio E, Sedano L, Barnadas A, Baiget M.

Pharmacogenomics J. 2008 Oct;8(5):315-20. Epub 2007 Aug 7. Erratum in: Pharmacogenomics J. 2009 Jun;9(3):218.

PMID:
17684476
23.

[Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital].

Artigas V, Marín-Hargreaves G, Marcuello E, Pey A, González JA, Rodríguez M, Moral A, Monill JM, Sancho J, Pericay C, Trias M.

Cir Esp. 2007 Jun;81(6):339-44. Spanish.

24.

Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.

Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A.

J Am Acad Dermatol. 2006 Sep;55(3):429-37. Epub 2006 Jul 13.

PMID:
16908348
25.

K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.

Céspedes MV, Sancho FJ, Guerrero S, Parreño M, Casanova I, Pavón MA, Marcuello E, Trias M, Cascante M, Capellà G, Mangues R.

Carcinogenesis. 2006 Nov;27(11):2190-200. Epub 2006 May 5.

PMID:
16679305
26.

Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.

Casanova I, Parreño M, Farré L, Guerrero S, Céspedes MV, Pavon MA, Sancho FJ, Marcuello E, Trias M, Mangues R.

Int J Cancer. 2006 May 15;118(10):2381-9.

27.

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

Marcuello E, Altés A, Menoyo A, Rio ED, Baiget M.

Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40. Epub 2005 Sep 27.

PMID:
16187112
28.

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Díaz-Rubio E; Cooperative Group for the Treatment of Digestive Tumors.

J Clin Oncol. 2005 May 20;23(15):3545-51.

PMID:
15908665
29.

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.

Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E.

Clin Colorectal Cancer. 2005 Mar;4(6):384-9.

PMID:
15807931
31.

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M.

Br J Cancer. 2004 Aug 16;91(4):678-82.

32.

Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.

Aranda E, Carrato A, Cervantes A, Sastre J, Gómez MA, Abad A, Masutti B, Ribera F, Marcuello E, Pronk L, Balcells M, Díaz-Rubio E; Grupo Español de Traitamiento de Tumores Digestivos.

Ann Oncol. 2004 Apr;15(4):559-67.

33.

Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.

Antón A, Aranda E, Carrato A, Marcuello E, Massutti B, Cervantes A, Abad A, Sastre J, Fenández-Martos C, Gallén M, Díaz-Rubio E, Huarte L, Balcells M; TTD cooperative group.

Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):639-43.

PMID:
14671682
34.

Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer.

Risques RA, Moreno V, Ribas M, Marcuello E, Capellà G, Peinado MA.

Cancer Res. 2003 Nov 1;63(21):7206-14.

35.

Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.

Pieras E, Palou J, Salvador J, Rosales A, Marcuello E, Villavicencio H.

Eur Urol. 2003 Aug;44(2):222-5; discussoion 225.

PMID:
12875942
36.

Mismatch repair gene analysis in Catalonian families with colorectal cancer.

Palicio M, Balmaña J, González S, Blanco I, Marcuello E, Peinado MA, Julià G, Germà JR, López López JJ, Brunet J, Capellà G.

J Med Genet. 2002 Jun;39(6):E29. No abstract available.

37.

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.

Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germá JR.

Br J Cancer. 2002 Feb 1;86(3):326-30.

38.

Redefining the significance of aneuploidy in the prognostic assessment of colorectal cancer.

Risques RA, Moreno V, Marcuello E, Petriz J, Cancelas JA, Sancho FJ, Torregrosa A, Capella G, Peinado MA.

Lab Invest. 2001 Mar;81(3):307-15.

39.

K-ras and p16 aberrations confer poor prognosis in human colorectal cancer.

Esteller M, González S, Risques RA, Marcuello E, Mangues R, Germà JR, Herman JG, Capellà G, Peinado MA.

J Clin Oncol. 2001 Jan 15;19(2):299-304.

PMID:
11208819
40.

Standardized approach for microsatellite instability detection in colorectal carcinomas.

González-García I, Moreno V, Navarro M, Martí-Ragué J, Marcuello E, Benasco C, Campos O, Capellà G, Peinado MA.

J Natl Cancer Inst. 2000 Apr 5;92(7):544-9.

PMID:
10749909
41.

[Identification of 2 families with hereditary nonpolyposis colonic cancer (HNPCC) and the Amsterdam criteria. Relevance of the genealogic tree and follow-up].

Balmaña J, Brunet J, Capellà G, González D, Palicio M, Sancho FJ, Pericay C, López López JJ, Marcuello E.

Med Clin (Barc). 2000 Jan 22;114(2):56-9. Spanish.

PMID:
10702951
42.

Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer.

Palicio M, Blanco I, Tórtola S, González I, Marcuello E, Brunet J, Lluis F, González-Aguilera JJ, Peinado MA, Capella G.

Br J Cancer. 2000 Feb;82(3):535-7.

43.

Prospective assessment of allelic losses at 4p14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival.

Arribas R, Ribas M, Risques RA, Masramon L, Tórtola S, Marcuello E, Aiza G, Miró R, Capellà G, Peinado MA.

Clin Cancer Res. 1999 Nov;5(11):3454-9.

44.

UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.

Díáz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallén M, Marcuello E, Rifá J, Massuti T, Cervantes A, Antón A, Fernández Martos C.

Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):35-40.

45.

Overall deregulation in gene expression as a novel indicator of tumor aggressiveness in colorectal cancer.

Tórtola S, Marcuello E, Risques RA, González S, Aiza G, Capellà G, Peinado MA.

Oncogene. 1999 Jul 29;18(30):4383-7.

46.

p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.

Tortola S, Marcuello E, González I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA, Capella G.

J Clin Oncol. 1999 May;17(5):1375-81.

PMID:
10334521
47.

Analysis of differential gene expression in human colorectal tumor tissues by RNA arbitrarily primed-PCR: a technical assessment.

Tórtola S, Capellà G, Marcuello E, Günther K, Aiza G, Masramon L, Reymond MA, Peinado MA.

Lab Invest. 1998 Mar;78(3):309-17.

PMID:
9520944
48.

A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).

Abad A, Navarro M, Sastre J, Marcuello E, Aranda E, Gallén M, Fernandez-Martos C, Martín C, Diaz-Rubio E.

Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):53-7.

49.

[Tricuspid and pulmonary valve in a case of carcinoid syndrome].

Alegret JM, Subirana MT, Marcuello E, Bayés-Genís A, Ferrés P, Torner M.

Rev Esp Cardiol. 1997 Jul;50(7):532-4. Spanish.

50.

Growing teratoma syndrome: experience of a single institution.

Maroto P, Tabernero JM, Villavicencio H, Mesía R, Marcuello E, Solé-Balcells FJ, Sola C, Mora J, Algaba F, Pérez C, León X, López López JJ.

Eur Urol. 1997;32(3):305-9.

PMID:
9358218

Supplemental Content

Loading ...
Support Center